SOURCE: CytoSorbents Corporation

CytoSorbents Corporation

September 23, 2011 07:30 ET

CytoSorbents Corporation to Exhibit at the European Society of Intensive Care Medicine Congress in Berlin and at the AdvaMed Conference in Washington D.C.

MONMOUTH JUNCTION, NJ--(Marketwire - Sep 23, 2011) - CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, announced that as part of its controlled-market release of CytoSorb™, it will exhibit at the European Society of Intensive Care Medicine Congress in Berlin, Germany from October 2-5, 2011 in Booth #71 at the International Congress Center Berlin. An estimated 6,000 medical personnel from across the world are expected to attend this largest European critical care conference. Dr. Phillip Chan, Chief Executive Officer stated, "Severe inflammation and cytokine-induced injury play a key role in many of the conditions targeted at the conference, including sepsis, acute respiratory distress syndrome, multiple organ failure, and trauma. Historically, however, therapies were not available to address these issues. CytoSorb™ is in a unique position to potentially fill this treatment gap, as a first-in-class cytokine filter that has demonstrated statistically significant reduction of cytokine storm in critically ill patients while improving patient outcome."

CytoSorbents also announced that it was selected to give a presentation of its technologies at the AdvaMed 2011 MedTech Conference in Washington, D.C. at the Walter E. Washington Convention Center on September 27, 2011 at 3:20PM EST in Room 204B. CytoSorbents will also exhibit during the conference from September 27-28th, in Booth # 206.

About CytoSorbents and CytoSorb™

CytoSorbents Corporation is a development stage, critical care-focused therapeutic device company using blood purification to treat life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and adsorption. In March 2011, CytoSorb™, the Company's flagship product, achieved European regulatory approval as an extracorporeal cytokine filter, and can now be sold throughout the European Union (E.U.) under the CE Mark to be used in cases where cytokines are elevated. To the Company's knowledge, this is the first E.U approved medical device to have the specific indication as a cytokine filter. The goal of CytoSorb™ is to modulate the immune system by removing excessive cytokines, often called "cytokine storm", in critically-ill patients that can lead to deadly inflammation, multiple organ failure, immune dysfunction, and often death. Cytokine storm frequently occurs in fatal diseases commonly seen in medical and surgical intensive care units, such as severe sepsis and septic shock, acute respiratory distress syndrome, serious burn and smoke inhalation injury, trauma and pancreatitis. Current standard of care therapies are mainly supportive and do little to hasten disease recovery. CytoSorb™ represents a new generation of "active" therapies, designed to counter cytokine storm and prevent or mitigate organ failure, potentially helping patients to heal and recover faster, leading to better patient outcome and reduced overall treatment costs. In the Company's recently completed European Sepsis Trial, CytoSorb™ treatment resulted in a statistically significant reduction of a number of key cytokines in patients with severe sepsis or septic shock, and respiratory failure. This was associated with a statistically significant reduction in 14-day mortality in patients older than 65 years of age, who make up approximately two-thirds of all hospitalized patients, and in 28-day mortality in patients with very high cytokine levels. Severe sepsis and septic shock afflicts more than 1 million people in the United States (U.S.), 1.5 million people in the E.U., and an estimated 18 million people worldwide each year, killing one in every three patients despite the best medical treatment. In the U.S., more die from severe sepsis than from either heart attacks, strokes or any single form of cancer. CytoSorb™ therapy is simple yet elegant. As blood is pumped repeatedly through the CytoSorb™ cartridge using standard dialysis equipment, the beads bind and remove cytokines and other toxins from blood. The treated blood is then returned to the patient. CytoSorb™ is currently manufactured under ISO 13485:2003 Full Quality Systems certification, an internationally recognized quality standard designed to ensure that medical device manufacturers have the necessary comprehensive management systems in place to safely design, develop, manufacture and distribute medical devices in the E.U. Assuming availability of adequate and timely funding, and continued positive results from our clinical studies, the Company intends to commercialize CytoSorb™ in Europe and then seek to commence U.S.-based clinical trials to obtain U.S. regulatory approval. CytoSorb™ is one of a number of different resins the Company has designed for various medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, rhabdomyolysis in trauma, removal of chemotherapy drugs during treatment of cancer with high dose regional chemotherapy, drug detoxification, and others. Additional information is available for download on the Company's website: www.cytosorbents.com

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. CytoSorbents Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and additional CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate and timely financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Form 10-K filed with the SEC on March 31, 2011, which is available at http://www.sec.gov.

Contact Information

  • Contact:

    CytoSorbents Corporation
    David Lamadrid
    Chief Financial Officer
    (732) 329-8885 ext. 816
    DavidL@cytosorbents.com